Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
September 07, 2023 17:00 ET
|
Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...
EHang Unmanned Aircraft Cloud System Approved by the CAAC; EH216-S Positioned for Post-TC Commercial Operations
August 21, 2023 09:19 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 21, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Reports Second Quarter 2023 Unaudited Financial Results
August 17, 2023 05:00 ET
|
EHang Holdings Limited
- All Planned Tests for EH216-S Type Certification Completed 100% - Strategic UAM Operational Partnership with Shenzhen Bao’an District - US$23 Million Strategic PIPE Investment to Strengthen...
Solve GNE and Genosera Sign Agreement to Develop a Novel Bicistronic AAV Gene Therapy Targeting HIBM
August 14, 2023 09:00 ET
|
Solve GNE LLC
LOS ANGELES, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Solve GNE announced today that it has entered into a sponsored research agreement with Genosera to provide funding for a novel Adeno-Associated Virus...
EHang to Report Second Quarter 2023 Unaudited Financial Results on Thursday, August 17, 2023
August 11, 2023 08:25 ET
|
EHang Holdings Limited
GUANGZHOU, China, Aug. 11, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang and Shenzhen Bao’an District Form Strategic Partnership for Urban Air Mobility Operation Center
July 13, 2023 08:32 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 13, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang Announces US$23 Million Private Placement Led by South Korean Strategic Investor Lee Soo Man
July 11, 2023 16:00 ET
|
EHang Holdings Limited
GUANGZHOU, China, July 12, 2023 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company”) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (“AAV”) technology platform company,...
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies for treatment of ophthalmic disease
June 01, 2023 05:09 ET
|
Rentschler Biopharma SE
Rentschler Biopharma to conduct adeno-associated virus (AAV) process development work for manufacturing scale-up at their ATMP site in Stevenage, UKIkarovec is developing novel gene therapies to treat...
Coave Therapeutics announces Positive 12-months Data from Ongoing Phase I/II Clinical Trial of CTx-PDE6b in Patients with Retinitis Pigmentosa Caused by Bi-allelic Mutations in PDE6b
May 31, 2023 06:00 ET
|
Coave Therapeutics
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
EHang Reports First Quarter 2023 Unaudited Financial Results
May 31, 2023 05:00 ET
|
EHang Holdings Limited
- Total Revenues Up 41.6% Quarter-over-Quarter- Continued High Quarterly Gross Margin of 60%+- EH216-S Type Certification’s Compliance Tests in Final Phase Completed More Than 90%- Notable Growth of...